We are monitoring the impact of COVID-19 on APAC Plasma Fractionation Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 2722
Share on
Share on

APAC Plasma Fractionation Market Research Report – Segmented By Product, Application, End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 2722
Pages: 145

APAC Plasma Fractionation Market Size (2021 to 2026)

The size of the Asia Pacific Plasma Fractionation Market is valued at USD 4.89 billion in 2021. This figure is projected to be growing at a CAGR of 9.6% to touch USD 7.73 billion by 2026.

Plasma, which constitutes about 55% of blood by volume, consists of several different proteins numbering into the thousands and other substances like minerals, hormones, etc. There are many therapeutic uses for the proteins present in plasma. For example, Albumin is commonly used to rejuvenate and maintain blood volume after traumatic injury, surgery, and plasma exchange.

The existence of government agencies that regulate and oversee plasma collection, fractionation, and sales and increase in respiratory diseases across Asia-Pacific are the major factors driving the plasma fractionation market forward.

The plasma fractionation market is also benefiting from favorable government assistance to raise awareness about the usage of plasma-derived products; the innovation and developments of the technologies will help increase the yield, faster throughput, and reduced costs.

Furthermore, rising occurrences of medical disorders, such as high fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary and secondary immunological deficiencies, are driving the industry forward. As well as the increase in the growth of market players and the geriatric population, which is more likely to have more occurrences that need plasma, is helping in the growth of the market.

High costs of the plasma products are manufactured from donated human blood. Clotting factor concentrates or fresh frozen plasma are made from plasma or clotting proteins that have been isolated or removed. However, plasma transfusion can cause unpleasant reactions or events, ranging from minor to deadly. In addition, a lack of awareness among people in rural areas leads to limited market growth. 

Due to the lack of a safe blood donor base and well-organized, nationally coordinated blood transfusion services, resulting in inconsistent screening and testing methods. Also, due to both financial and human resources are in short supply as well as insufficient remuneration.

This research report on the APAC plasma fractionation market has been segmented and sub-segmented into the following categories:

By Product: 

  • Albumin
  • Immunoglobulin
  • Factor VIII
  • Protease Inhibitors

By Application: 

  • Neurology
  • Hematology
  • Rheumatology
  • Pulmonology
  • Immunology

By End User: 

  • Hospitals
  • Clinical Laboratories

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the APAC market is anticipated to witness a prominent share in the global market during the forecast period. The market growth is attributed to the increasing population and as well geriatric population across the region. Therefore, by 2050, the number of elderly persons in Asia-Pacific would have tripled, reaching 1.3 billion. Women make up the majority (53%) of the region's population aged 60 and over, and their proportion climbs to 60% at the age of 80.

Japan has the highest proportion of the aging population, with 33.1 percent. On the other hand, China leads with its total population with 11.9 percent of the elderly population. India is the other leading position with the largest population with 6.1 percent of the elderly population.

The increase in respiratory diseases across the Asia-Pacific is due to air pollution, smoking, and overweight in the region. Further, the market players present in the market in these regions like Grifols S.A., Bharat Serum and Vaccine Limited (BSV), China Biologic Product Holdings, Inc., and many more are competing with each other to expand their business, also due to the increase in the technological advancements with improved accessibility. These factors, as well as numerous strategic initiatives undertaken by these industries and market players to extend their regional presence and product reach, will impact the industry development in this region.

KEY MARKET PLAYERS:

Some of the notable companies leading the Asia Pacific plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product                        

                                5.1.1 Introduction           

                                5.1.2 Fractionation Process         

                                5.1.3 Immunoglobulin   

                                5.1.4 Coagulation Factor Concentrates  

                                5.1.5 Albumin   

                                5.1.6 Protease Inhibitors              

                                5.1.7  Y-o-Y Growth Analysis, By Product              

                                5.1.8  Market Attractiveness Analysis, By Product            

                                5.1.9  Market Share Analysis, By Product              

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Neurology               

                                5.2.3 Immunology           

                                5.2.4 Hematology            

                                5.2.5 Critical Care             

                                5.2.6 Pulmonology          

                                5.2.7 Hemato-Oncology               

                                5.2.8 Rheumatology       

                                5.2.9 Other Application 

                                5.2.10 Y-o-Y Growth Analysis, By Application      

                                5.2.11 Market Attractiveness Analysis, By Application    

                                5.2.12 Market Share Analysis, By Application      

                5.3 End User                      

                                5.4.1 Introduction           

                                5.4.2 Hospitals  

                                5.4.3 Clinical Laboratories            

                                5.4.4 Academic Institutes            

                                5.4.5 Y-o-Y Growth Analysis, By End User             

                                5.4.6  Market Attractiveness Analysis, By End User          

                                5.4.7  Market Share Analysis, By End User            

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Application

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Application

                                                6.1.4.4 By End User

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Application

                                                6.1.5.4 By End User

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Baxalta Incorporated                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 CSL Ltd.                        

                8.3 Grifols S.A                   

                8.4 Octapharma AG                        

                8.5 Kedrion S.p.A                            

                8.6 Bio Products Laboratory                        

                8.7 Sanquin                        

                8.8 China Biologic Products, Inc.                

                8.9 Biotest AG                  

                8.10 Laboratoire Français du Fractionnement et des Biotechnologies                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  2. Asia-Pacific Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  3. Asia-Pacific Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  4. Asia-Pacific Albumin Market, By Region, From 2021 to 2026 (USD Million)
  5. Asia-Pacific Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  6. Asia-Pacific Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  7. Asia-Pacific Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  8. Asia-Pacific Neurology Market, By Region, From 2021 to 2026 (USD Million)
  9. Asia-Pacific Immunology Market, By Region, From 2021 to 2026 (USD Million)
  10. Asia-Pacific Hematology Market, By Region, From 2021 to 2026 (USD Million)
  11. Asia-Pacific Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  12. Asia-Pacific Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  13. Asia-Pacific Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  14. Asia-Pacific Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  15. Asia-Pacific Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  16. Asia-Pacific Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  17. Asia-Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  18. Asia-Pacific Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  19. Asia-Pacific Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  20. Japan Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  21. Japan Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  22. Japan Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  23. China Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  24. China Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  25. China Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  26. India Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  27. India Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  28. India Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  29. Australia Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  30. Australia Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  31. Australia Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  32. South Korea Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  33. South Korea Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  34. South Korea Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample